Understanding Hemophilia A and B Drug Dosage Administration Patterns

Back to Search
Print
Bookmark Trial

NCT03248141

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
University of Florida College of Medicine
Gainesville, Florida, 32610, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hemophilia A, Hemophilia B
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Female with hemophilia A or B


- Mild Haemophilia A or B

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Hemophilia A, Hemophilia BTreatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study
NCT02740413
ALL GENDERS
0+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BStudy of the Efficacy and Safety PF-06741086 in Adult and Teenage Patients With Severe Hemophilia A or B
NCT03938792
  1. Iowa City, Iowa
  2. Paris,
  3. Jeollanam-do,
  4. Little Rock, Arkansas
  5. Tampa, Florida
  6. New Hyde Park, New York
  7. Melbourne, Victoria
  8. Parkville, Victoria
  9. Rio de Janeiro, RJ
  10. Pleven,
  11. Sofia,
  12. Hamilton, Ontario
  13. Hamilton, Ontario
  14. Frankfurt am Main,
  15. Hong Kong,
  16. Hong Kong,
  17. Surat, Gujarat
  18. Pune, Maharashtra
  19. Pune, Maharashtra
  20. Dublin 12,
  21. Nagoya, Aichi
  22. Kashihara, Nara
  23. Fuchu, Tokyo
  24. Setagaya-ku, Tokyo
  25. Hiroshima,
  26. Daegu,
  27. Daejeon,
  28. Seoul,
  29. Seoul,
  30. Monterrey, Nuevo LEON
  31. Mérida, Yucatán
  32. Muscat,
  33. Samara,
  34. Belgrade,
  35. Belgrade,
  36. Kragujevac,
  37. Nis,
  38. Novi Sad,
  39. Palma de Mallorca, Islas Baleares
  40. Madrid,
  41. Valencia,
  42. Changhua City, Changhua County
  43. Kaohsiung,
  44. Taipei,
  45. Adana,
  46. Ankara,
  47. Ankara,
  48. Antalya,
  49. Gaziantep,
  50. Istanbul,
  51. Istanbul,
  52. Izmir,
  53. Izmir,
  54. Kayseri,
  55. Samsun,
  56. Trabzon,
Male
12 Years+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BUnderstanding Hemophilia A and B Drug Dosage Administration Patterns
NCT03248141
  1. Gainesville, Florida
  2. Las Vegas, Nevada
  3. Fort Worth, Texas
ALL GENDERS
0+
years
MULTIPLE SITES
Hemophilia A, Hemophilia BStudy Evaluating Approach to Treatment of Haemophilia A and B in Spain
NCT00581438
ALL GENDERS
0+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title Understanding Hemophilia A and B Drug Dosage Administration Patterns
Official Title UNDERSTANDING HEMOPHILIA A AND B DRUG DOSAGE ADMINISTRATION PATTERNS
Brief Summary

Study Design

A prospective observational, cross-sectional epidemiological study in U.S. site-based clinical practice settings.

30 sites will enroll approximately 300 patients

Participating patients - or their caregiver in the case of patients under the age of 18 - will be consented to participate.

Physicians complete a retrospective chart review on each enrolled patient.

Patients will complete a one-time study questionnaire.

Detailed Description Study recruitment was stopped due to difficulty in enrolling the targeted number of patients on March 21, 2018. Subjects currently enrolled into the study have completed the study as per protocol. There were no safety concerns involved in the decision to stop enrollment.
Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Other
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Patients diagnosed with either hemophilia A or B who present for a routine Clinical visit will be asked to participate in the study by the treating physician at participating hemophilia treatment centers in the United States of America.
Condition
  • Hemophilia A
  • Hemophilia B
Intervention
  • Drug: Hemophilia B standard half-life
    Benefix
  • Drug: Hemophilia B extended half-life
    Alprolix
  • Drug: Hemophilia A standard half-life
    Xyntha and other standard half-life agents
  • Drug: Hemophilia A extended half-life
    Eloctate and Adynovate
Study Groups/Cohorts
  • Hemophilia B
    real world administration patterns and resource utilization implications
    Interventions:
    • Drug: Hemophilia B standard half-life
    • Drug: Hemophilia B extended half-life
  • Hemophilia A
    real world administration patterns and resource utilization implications
    Interventions:
    • Drug: Hemophilia A standard half-life
    • Drug: Hemophilia A extended half-life
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Terminated
Actual Enrollment
 (submitted: February 22, 2019)		11
Original Estimated Enrollment
 (submitted: August 9, 2017)		300
Actual Study Completion Date March 14, 2018
Actual Primary Completion Date March 14, 2018   (Final data collection date for primary outcome measure)
Eligibility Criteria

Physician/Clinician Participants:

  • Must be a healthcare provider
  • Currently manages at least 10 hemophilia A and/or B patients

Patient Participants:

  • Willing and able to provide informed consent
  • Diagnosed with hemophilia A or B
  • Current disease severity is either moderately severe or severe with a clotting factor level of ?5%
  • If suffering from hemophilia A, must be currently taking moroctocog alfa (or another standard half-life treatment), rurioctocog alfa or efraloctocog alfa for at least six months.

(If currently taking rurioctocog alfa or efraloctocog alfa, must have been switched from a standard half-life treatment and had been on that prior treatment for at least six months).

  • If suffering from hemophilia B, must be currently taking nonacog alfa or eftrenonacog alfa for at least six months (If currently taking eftrenonacog alfa, must have switched from nonacog alfa and had been on that prior treatment for at least six months).
  • Infuse at least 3 times per month

Exclusion criteria:

  • Female with hemophilia A or B
  • Mild Haemophilia A or B
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT03248141
Other Study ID Numbers B1821056
HEMOBAFS ( Other Identifier: Alias Study Number )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
IPD Sharing Statement
Plan to Share IPD:No
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
Responsible Party Pfizer
Study Sponsor Pfizer
Collaborators Not Provided
Investigators
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date February 2019